20 research outputs found

    MicroRNA-126 inhibits cell invasion and tumor growth.

    No full text
    <p>(A) Overe-xpression of microRNA-126 inhibits the cell invasion in A549 and SK-MES-1 cells. Compared with the control group, over-expression of microRNA-126 impaires cell invasion. (B) MicroRNA-126 impairs the cell proliferation in A549 and SK-MES-1 cells. The cell proliferation was dramatically decreased after cells were treated with microRNA-126 over-expression for 72 hours. (C) The tumor growth curve <i>in vivo</i> by intratumoral injection with microRNA-126. The growth of tumors was observed from 1 to 25 days after the last injection. (D) MicroRNA-126 inhibits growth of A549 cell and SK-MES-1 cells in vivo. The average tumor only about an half of the tumors weight in the mice treated with PBS or pE-CMV vector alone.</p

    Genotype of microRNA-126 polymorphisms and their associations with NSCLC risk.

    No full text
    <p>Genotype of microRNA-126 polymorphisms and their associations with NSCLC risk.</p

    The expression levels of microRNA-126 in Non-small cell lung cancers.

    No full text
    <p>The expression levels of microRNA-126 in Non-small cell lung cancers.</p

    Genetic variant within microRNA-126 is not associated with the survival times and microRNA-126 expression levels in NSCLC patients.

    No full text
    <p>(A) Genetic variant within microRNA-126 is not associated with survival times. Kaplan-Meier survival estimates show that there is no association between SNP rs4636297 and survival time in NSCLC patients (<i>P</i> = 0.992). (B). Expression levels of microRNA-126 in NSCLC tissues of three genotypes are similar. MicroRNA-126 expression was determined by quantitative real-time PCR. There was no significant difference among the three genotype groups (<i>P</i> = 0.972).</p

    Table_1_Clinical, neurophysiological evaluation and genetic features of axonal Charcot–Marie–Tooth disease in a Chinese family.doc

    No full text
    Charcot–Marie–Tooth disease (CMT) is a group of inherited peripheral neuropathies related to variants in the mitochondrial transfer RNA (mt-tRNAval) gene. Here, we report a Chinese family harboring the m.1661A>G variant in the mt-tRNAval gene. Clinical evaluation, neuroelectrodiagnostic testing, and nerve biopsy were performed on four affected family members. Weakness, spasms, and pain in the limbs (especially in the lower limbs) were the main complaints of the proband. Physical examination revealed atrophy and weakness in the distal limbs, increased muscle tone, and hyperreflexia in four limbs. Neuroelectrodiagnostic tests and nerve biopsy supported an axonal polyneuropathy. This study furthers the understanding of phenotype diversity caused by variants in the mt-tRNAval gene in CMT.</p

    Clinical features of KBD patients.

    No full text
    <p>A. A female KBD patient with her knee, ankle and toe joints deformity, the arrows show multiple joints of this patient are affected. B. A male KBD patient with his fingers joints deformity. C. The X-ray picture of a KBD patient's hand.</p

    Iodine and GPXs involved in Thyroid Hormones Biosynthesis.

    No full text
    <p>The serum sodium iodide is transported into the thyrocyte and then iodine is incorporated into the thyroglobulin molecule (Tg) in a reaction catalyzed by the hemoprotein thyroid peroxidase (TPO). In this reaction, H<sub>2</sub>O<sub>2</sub> generated by the NADPH-dependent thyroxidase (ThOx) is required as substrate by TPO for the iodination and coupling of tyrosyl residues in Tg. Then, thyroid hormones triiodothyronine (T3) and tetraiodothyronine (T4) are released into the bloodstream. H<sub>2</sub>O<sub>2</sub> used in this reaction decreases the amount of H<sub>2</sub>O<sub>2</sub> that would otherwise be available for damaging oxidation reactions. Selenium-dependent glutathione peroxidase 1 (<i>GPX 1</i>) and other GPX s remove H<sub>2</sub>O<sub>2</sub> from the tissues, also decreasing oxidative damage. (Modified from: J. Köhrle <i>et al</i>. Selenium, the thyroid, and the endocrine system. Endocrine Reviews, December 2005, 26(7):944–984; Lyn Patrick, ND. Iodine: deficiency and therapeutic considerations. Alternative Medicine Review, 2008, 13(2):116–127).</p
    corecore